Wallin B A, McCafferty J P, Fox M J, Cooper D R, Goldschmidt M S
Medical Affairs Department, Smith Kline and French Laboratories, Philadelphia, PA 19101.
J Rheumatol. 1988 Dec;15(12):1755-8.
The incidence, severity, and management of diarrhea during longterm administration of auranofin (AF)--up to 33 months--were evaluated prospectively in 137 patients with active rheumatoid arthritis. At least 1 episode of diarrhea was reported in 101 patients (74%), but the rate of occurrence/patient-months of therapy was 24% (569 events/2,370 patient-months of treatment). The monthly prevalence declined from a range of 30-40% during the initial 6 months to about 10% for patients treated for 18-24 months. Most diarrhea was intermittent and mild; only 11 patients (8%) discontinued treatment because of diarrheal symptoms. No intervention was required in 46 of the 101 patients affected. In 44 others, loose stools were successfully managed with antidiarrheal medications, a reduction in dosage, or both. Although diarrhea is a common event during AF administration, particularly early in therapy, for most patients it usually does not significantly interfere with treatment.
对137例活动性类风湿关节炎患者进行前瞻性评估，观察金诺芬（AF）长期给药（长达33个月）期间腹泻的发生率、严重程度及处理情况。101例患者（74%）报告至少出现过1次腹泻，但每治疗患者月的发生率为24%（2370患者月的治疗中出现569次腹泻事件）。最初6个月期间每月患病率在30% - 40%，而治疗18 - 24个月的患者每月患病率降至约10%。多数腹泻为间歇性且症状轻微；仅11例患者（8%）因腹泻症状停药。101例受影响患者中46例无需干预。另外44例患者通过止泻药物、减少剂量或两者并用成功处理了稀便。虽然腹泻在服用AF期间常见，尤其在治疗早期，但对多数患者而言，腹泻通常不会显著干扰治疗。
